Arylamine N-acetyltransferases

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 2, 2007, Pages 169-184

  Sim, Edith ^a   Westwood, Isaac ^a   Fullam, Elizabeth ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arylamine N acetyltransferase; Folate; NAT; Pharmacogenetics; Tuberculosis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 1; ARYLAMINE ACETYLTRANSFERASE 2; DAPSONE; DRUG METABOLIZING ENZYME; FOLIC ACID; HYDRAZINE DERIVATIVE; ISONIAZID; PROCAINAMIDE; RIFAMPICIN; SULFADIMIDINE; SULFONAMIDE; UNCLASSIFIED DRUG;

ACETYLATION; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIAL SURVIVAL; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; CRYSTAL STRUCTURE; DISEASE MODEL; DNA SEQUENCE; DRUG METABOLISM; ENZYME INACTIVATION; ENZYME STRUCTURE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; HUMAN; MACROPHAGE; MYCOBACTERIUM SMEGMATIS; NEURAL TUBE DEFECT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACOGENETICS; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS; REVIEW; SALMONELLA TYPHIMURIUM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPINA BIFIDA; TRANSGENIC ANIMAL; TUBERCULOSIS; AMINO ACID SEQUENCE; ANIMAL; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE;

CORYNEBACTERINEAE; MUS MUSCULUS;

AMINO ACID SEQUENCE; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; CATALYSIS; EVOLUTION, MOLECULAR; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, SECONDARY;

EID: 34547180380     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.2.169     Document Type: Review

References (150)

1. BONICKE R, REIF W: Enzymatic inactivation of isonicotinic acid hydrazide in human and animal organism. Arch. Exp. Pathol. Pharmak. (1953) 220(4):321-323.
2. EVANS DA, MANLEY KA, MCKUISICK VA: Genetic control of isoniazid acetylation in man. Br. Med. J. (1960) 2:485-491.
3. KALOW W: Ethnic differences in drug metabolism. Clin. Pharmacokinet. (1982) 7(5):373-400.
4. WEBER WW: Populations and genetic polymorphisms. Mol. Diagn. (1999) 4(4):299-307.
5. WEBER WW, HEIN DW: N-acetylation pharmacogenetics. Pharmacol. Rev. (1985) 37(1):25-79.
6. EVANS DA: N-acetyltransferase. Pharmacol. Ther. (1989) 42(2):157-234.
7. JENNE JW: Partial purification and properties of the isoniazid transacetylasc in human liver: its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Invest. (1965) 44:1992-2002.
8. MITCHELL RS, BELL JC: Clinical implications of isoniazid, PAS and streptomycin blood levels in pulmonary tuberculosis. Trans. Am. Clin. Climatol. Assoc. (1957) 69:98-102.
9. CARTWRIGHT RA, GLASHAN RW, ROGERS HJ et al.: Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet (1982) 16(2):842-845.
10. RISCH A, WALLACE DM, BATHERS S, SIM E: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. (1995) 4(2):231-236.
11. HEIN DW: N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene (2006) 25(11):1649-1658.
12. CARREON T, RUDER AM, SCHULTE PA et al.: NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int. J. Cancer (2006) 118(1):161-168.
13. CHANG-CLAUDE J, KROPP S, JAGER B, BARTSCH H, RISCH A: Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. (2002) 11(8):698-704.
14. ISHIBE N, SINHA R, HEIN DW et al.: Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics (2002) 12(2):145-150.
15. BORLAK J, REAMON-BUETTNER SM: N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med. Genet. (2006) 7:58.
16. CHOU TC, LIPMANN F: Separation of acetyl transfer enzymes in pigeon liver extract. J. Biol. Chem. (1952) 196(1):89-103.
17. RIDDLE B, JENCKS WP: Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. (1971) 246(10):3250-3258.
18. OHSAKO S, OHTOMI M, SAKAMOTO Y, UYEMURA K, DEGUCHI T: Arylamine N-acetyltransferase from chicken liver II. Cloning of cDNA and expression in Chinese hamster ovary cells. J. Biol. Chem. (1988) 263(16):7534-7538.
19. LIPMANN F: On chemistry and function of coenzyme A. Bacteriol Rev. (1953) 17(1):1-16.
20. WATANABE M, SOFUNI T, NOHMI T: Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J. Biol. Chem. (1992) 267(12):8429-8436.
21. SINCLAIR JC, SANDY J, DELGODA R, SIM E, NOBLE ME: Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. (2000) 7(7):560-564.
22. HOLTON SJ, DAIROU J, SANDY J et al.: Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta Crystallogr. F (2005) 61:14-16.
23. ZHANG N, LIU L, LIU F et al.: NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. (2006) 363(1):188-200.
24. WESTWOOD IM, HOLTON SJ, RODRIGUES-LIMA F et al.: Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem. J. (2005) 385(2):605-612.
25. PAYTON M, MUSHTAQ A, YU TW et al.: Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiology (2001) 147(5):1137-1147.
26. RODRIGUES-LIMA F, DUPRET JM: In silico sequence analysis of arylamine N-acetyltransferases: evidence for an absence of lateral gene transfer from bacteria to vertebrates and first description of paralogs in bacteria. Biochem. Biophys. Res. Commun. (2002) 293(2):783-792.
27. SANDY J, MUSHTAQ A, HOLTON SJ et al.: Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem. J. (2005) 390(1):115-123.
28. BOUKOUVALA S, FAKIS G: Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab. Rev. (2005) 37(3):511-564.
29. WANG H, LIU L, HANNA PE, WAGNER CR: Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry (2005) 44(33):11295-11306.
30. SUGAMORI KS, WONG S, GAEDIGK A et al.: Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol. Pharmacol. (2003) 64(1):170-179.
31. CORNISH VA, PINTER K, BOUKOUVALA S et al.: Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J. (2003) 3 (3):169-177.
32. BHAKTA S, BESRA GS, UPTON AM et al.: Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J. Exp. Med. (2004) 199(9):1191-1199.
33. CAO W, CHAU B, HUNTER R et al.: Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics J. (2005) 5(4):255-261.
34. FAKIS G, BOUKOUVALA S, BUCKLE V et al.: Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2. Cytogenet. Cell Genet. (2000) 90(1-2):134-138.
35. BUTCHER NJ, ILETT KF, MINCHIN RF: Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol. Pharmacol. (2000) 57(3):468-473.
36. LIU F, ZHANG N, ZHOU X et al.: Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. (2006) 361(3):482.
37. POMPEO F, BROOKE E, KAWAMURA A, MUSHTAQ A, SIM E: The pharmacogenetics of NAT: structural aspects. Pharmacogenomics (2002) 3(1):19-30.
38. DUPRET JM, RODRIGUES-LIMA F: Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr. Med. Chem. (2005) 12(3):311-318.
39. WESTWOOD IM, KAWAMURA A, FULLAM E et al.: Structure and mechanism of arylamine N-acetyltransferases. Curr. Top. Med. Chem. (2006) 6(15):1641-1654.
40. BROCKTON N, LITTLE J, SHARP L, COTTON SC: N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am. J. Epidemiol. (2000) 151(9):846-861.
41. HEIN DW, DOLL MA, FRETLAND AJ et al.: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. (2000) 9(1):29-42.
42. LILLA C, VERLA-TEBIT E, RISCH A et al.: Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol. Biomarkers Prev. (2006) 15(1):99-107.
43. MITCHELL KR, WARSHAWSKY D: Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes. Toxicol. Lett. (2003) 139(1):11-23.
44. EBISAWA T, DEGUCHI T: Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem. Biophys. Res. Commun. (1991) 177(3):1252-1257.
45. PATIN E, BARREIRO LB, SABETI PC et al.: Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am. J. Hum. Genet. (2006) 78 (3):423-436.
46. ZHU Y, HEIN DW, DOLL MA et al.: Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay. Clin. Chem. (2006) 52(6):1033-1039.
47. SABBAGH A, DARLU P: SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype. Genet. Med. (2006) 8(2):76-85.
48. BLUM M, DEMIERRE A, GRANT DM, HEIM M, MEYER UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA (1991) 88(12):5237-5241.
49. ZHU Y, DOLL MA, HEIN DW: Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2. J. Biol. Chem. (2002) 383(6):983-987.
50. ZHANG Y, ZHAO S, DOLL MA, STATES JC, HEIN DW: The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenet. Genomics (2004) 14(11):717-723.
51. SUMMERSCALES JE, JOSEPHY PD: Human acetyl CoA:arylamine N-acetyltransferase variants generated by random mutagenesis. Mol. Pharmacol. (2004) 65(1):220-226.
52. SAVULESCU MR, MUSHTAQ A, JOSEPHY PD: Screening and characterizing human NAT2 variants. Methods Enzymol. (2005) 400:192-215.
53. HEIN DW, FRETLAND AJ, DOLL MA: Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int. J. Cancer (2006) 119(5):1208-1211.
54. GOODFELLOW GH, DUPRET JM, GRANT DM: Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. (2000) 348(1):159-166.
55. KAWAMURA A, GRAHAM J, MUSHTAQ A et al.: Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. (2005) 69(2):347-359.
56. BUTCHER NJ, ILETT KF, MINCHIN RF: Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics (1998) 8(1):67-72.
57. BUTCHER NJ, ARULPRAGASAM A, MINCHIN RF: Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. (2004) 279(21):22131-22137.
58. DAIROU J, ATMANE N, RODRIGUES-LIMA F, DUPRET JM: Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase I (NAT1) in human breast cancer cells: a cellular and mechanistic study. J. Biol. Chem. (2004) 279(9):7708-7714.
59. DAIROU J, MALECAZE F, DUPRET JM, RODRIGUES-LIMA F: The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol. Pharmacol. (2005) 67(4):1299-1306.
60. BUTLER JS, LOH SN: Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature. Protein Sci. (2006) 15(11):2457-2465.
61. JOERGER AC, ANG HC, FERSHT AR: Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad Sci. USA (2006) 103(41):15056-15061.
62. WANG L, YEE VC, WEINSHILBOUM RM: Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. Biochem. Biophys. Res. Commun. (2004) 325(2):426-433.
63. NAGAR S, WALTHER S, BLANCHARD RL: Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol. Pharmacol. (2006) 69(6):2084-2092.
64. BLUM M, GRANT DM, MCBRIDE W, HEIM M, MEYER UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. (1990) 9(3):193-203.
65. MATAS N, THYGESEN P, STACEY M, RISCH A, SIM E: Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet. Cell Genet. (1997) 77(3-4):290-295.
66. STACEY M, MATAS N, DRAKE M et al.: Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novel NAT1 cosmid clone: an investigation in bladder cancer by interphase FISH. Genes Chromosomes Cancer (1999) 25(4):376-383.
67. POLE JC, COURTAY-CAHEN C, GARCIA MJ et al.: High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene (2006) 25(41):5693-5706.
68. BUTCHER NJ, ARULPRAGASAM A, GOH HL, DAVEY T, MINCHIN RF: Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem. J. (2005) 387(1):119-127.
69. BOUKOUVALA S, PRICE N, PLANT KE, SIM E: Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice. Biochem. J. (2003) 375(3):593-602.
70. SMELT VA, MARDON HJ, SIM E: Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol. Toxicol. (1998) 83(4):149-157.
71. UPTON A, JOHNSON N, SANDYJ, SIM E: Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol. Sci. (2001) 22(3):140-146.
72. ZHANGWEI X, JIANMING X, QIAO M, XINHUA X: N-acetyltransferase-1 gene polymorphisms and correlation between genotype and its activity in a central Chinese Han population. Clin. Chim. Acta (2006) 371(1-2):85-91.
73. HAYES RB, BI W, ROTHMAN N et al.: N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis (1993) 14(4):675-678.
74. TAIOLI E: International collaborative study on genetic susceptibility to environmental carcinogens. Cancer Epidemiol. Biomarkers Prev. (1999) 8(8):727-728.
75. VINEIS P, MARINELLI D, AUTRUP H et al.: Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol. Biomarkers Prev. (2001) 10(12):1249-1252.
76. GARTE S, GASPARI L, ALEXANDRIE AK et al.: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. (2001) 10(12):1239-1248.
77. SMELT VA, UPTON A, ADJAYE J et al.: Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum. Mol. Genet. (2000) 9(7)1101-1107.
78. CRIBB AE, GRANT DM, MILLER MA, SPIELBERG SP: Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J. Pharmacol. Exp. Ther. (1991) 259(3):1241-1246.
79. PAYTON MA, SIM E: Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem. Pharmacol. (1998) 55(3):361-366.
80. JOHNSON N, TROEN A, FERNANDO S AL: Investigation of N-acetyltransferase (NAT1) in Alzheimer's disease: identification of a novel NAT1 allelic variant. EUROTOX. London, UK (2000).
81. STANLEY LA, COPP AJ, POPE J et al.: Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology (1998) 58(5):174-182
82. MO M, CORNISH V, TROEN A et al.: Arylamine N-acetyltransferase in neural tissue. Third International Workshop on Arylamine N-acetyltransferases. Vancouver, Canada (2004).
83. PACIFICI GM, BENCINI C, RANE A: Acetyltransferase in humans: development and tissue distribution. Pharmacology (1986) 32(5):283-291.
84. MITCHELL MK, FUTSCHER BW, MCQUEEN CA: Developmental expression of N-acetyltransferases in C57B1/6 mice. Drug Metab. Dispos. (1999) 27(2):261-264.
85. MCQUEEN CA, MITCHELL MK, DANG LN et al.: Prenatal expression of N-acetyltransferases in C57B1/6 mice. Chem. Biol. Interact. (2003) 145(1):77-87.
86. MCQUEEN CA, CHAU B: Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity. Toxicol. Sci. (2003) 73(2):279-286.
87. WAKEFIELD L, CORNISH V, BROACKES-CARTER F, SIM E: Arylamine N-acetyltransferase 2 expression in the developing heart. J. Histochem. Cytochem. (2005) 53(5):583-592.
88. JENSEN LE, HOESS K, MITCHELL LE, WHITEHEAD AS: Loss of function polymorphisms in NAT1 protect against spina bifida. Hum. Genet. (2006) 120(1):52-57.
89. LAMMER EJ, SHAW GM, IOVANNISCI DM, FINNELL RH: Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. Birth Defects Res. A. Clin. Mol. Teratol. (2004) 70(11):846-852.
90. CARMICHAEL SL, SHAW GM, YANG W, IOVANNISCI DM, LAMMER E: Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake. Am. J. Med Genet. A (2006) 140(18):1915-1922.
91. MINCHIN RF: Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. (1995) 307(1):1-3.
92. WARD A, SUMMERS MJ, SIM E: Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem. Pharmacol. (1995) 49(12):1759-1767.
93. STANISLAWSKA-SACHADYN A, JENSEN LE, KEALEY C et al.: Association between the NAT1 1095C > A polymorphism and homocysteine concentration. Am. J. Med. Genet. A (2006) 140(21):2374-2377.
94. BELL DA, BADAWI AF, LANG NP et al.: Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. (1995) 55(22):5226-5229.
95. BRUHN C, BROCKMOLLER J, CASCORBI I, ROOTS I, BORCHERT HH: Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem. Pharmacol. (1999) 58(11):1759-1764.
96. HUGHES NC, JANEZIC SA, MCQUEEN KL et al.: Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics (1998) 8(1):55-66.
97. GRANT DM, HUGHES NC, JANEZIC SA et al.: Human acetyltransferase polymorphisms. Mutat. Res. (1997) 376(1-2):61-70.
98. JOHNSON N, BELL P, JONOVSKA V. BUDGE M, SIM E: NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant. BMC Med. Genet. (2004) 5:6.
99. CLARKE R, SMITH AD, JOBST KA et al.: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch. Neurol. (1998) 55(11):1449-1455.
100. HUSAIN A, BARKER DF, STATES JC, DOLL MA, HEIN DW: Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics (2004) 14 (7):397-406.
101. BOUKOUVALA S, SIM E: Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin. Pharmacol. Toxicol. (2005) 96(5):343-351.
102. BARKER DF, HUSAIN A, NEALE JR et al.: Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet. Genomics (2006) 16 (7):515-525.
103. BUTCHER NJ, ARULPRAGASAM A, POPE C, MINCHIN RF: Identification of a minimal promoter sequence for the human N-acetyltransferase type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). Biochem. J. (2003) 376(2):441-448.
104. ADAM PJ, BERRY J, LOADER JA et al.: Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. (2003) 1(11):826-835.
105. VAN DE VIJVER MJ, HE YD, VANT VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347(25):1999-2009.
106. WANG Y, KLIJN JG, ZHANG Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 365(9460):671-679.
107. ZHAO H, LANGEROD A, JI Y et al.: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell (2004) 15(6):2523-2536.
108. PEROU CM, JEFFREY SS, VAN DE RIJN M et al.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA (1999) 96(16):9212-9217.
109. MATTANO SS, ERICKSON RP, NESBITT MN, WEBER WW: Linkage of Nat and Es-1 in the mouse and development of strains congenic for N-acetyltransferase. J. Hered. (1988) 79(6):430-433.
110. KELLY SL, SIM E: Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem. J. (1994) 302(2):347-353.
111. BOUKOUVALA SPRICE N, SIM E: Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics (2002) 12(5):385-394.
112. WALRAVEN JM, DOLL MA, HEIN DW: Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2. J. Pharmacol. Exp. Ther. (2006) 319(1):369-375.
113. ILETT KF, KADLUBAR FF, MINCHIN RF: 1998 International Meeting on the Arylamine N-Acetyltransferases: synopsis of the workshop on nomenclature, biochemistry molecular biology, interspecies comparisons, and role in human disease risk. Drug Metab. Dispos. (1999) 27(9):957-959.
114. RODRIGUES-LIMA F, BLOMEKE B, SIM E, DUPRET JM: NAT - from bugs to brains. An overview of the 2nd International Workshop on the arylamine N-acetyltransferases. Pharmacogenomics J. (2002) 2(3):152-155.
115. WANG H, VATH GM, KAWAMURA A et al.: Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. (2005) 24(2):65-77.
116. LEVY GN, MARTELL KJ, DELEON JH, WEBER WW: Metabolic, molecular genetic and toxicological aspects of the acetylation polymorphism in inbred mice. Pharmacogenetics (1992) 2(5): 197-206.
117. DELEON JH, MARTELL KJ, VATSIS KP, WEBER WW: Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). Drug Metab. Dispos. (1995) 23 (12):1354-1361.
118. LEFF MA, EPSTEIN PN, DOLL MA et al.: Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther. (1999) 290(1):182-187.
119. SUGAMORI K, WONG S, BRENNAN D, LU X, GRANT D: Nat3 knockout or overexpression in mice has no influence on N-acetylation activity. Drug Metab. Rev. (2004) 36:164.
120. SUGAMORI KS, BRENNEMAN D, GRANT DM: In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice. Drug Metab. Dispos. (2006) 34(10):1697-1702.
121. LOEHLE JA, CORNISH V, WAKEFIELD L et al.: N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J. Pharmacol. Exp. Ther. (2006) 319(2):724-728.
122. WAKEFIELD L, KAWAMURA A, LONG H, SIM E: Neuroendocrine expression of mouse arylamine N-acetyltransferase 2. Genet. Res. (2006) 88(1):74.
123. SIM E, PINTER K, MUSHTAQ A et al.: Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. (2003) 31(3):615-619.
124. PINTER K, GARDNER R, WOOD F, SIM E: Effect of overexpression of human NAT1 in mice. 2nd International NAT workshop. Eynsham, UK (2001).
125. LIU SL, ERICKSON RP: Genetic differences among the A/J X C57BL/6J recombinant inbred mouse lines and their degree of association with glucocorticoid-induced cleft palate. Genetics (1986) 113(3):745-754.
126. WAKEFIELD L, CORNISH V, LONG H et al.: The expression of mouse arylamine N-acetyltransferase 2 (Nat2) in the developing neuroendocrine system. BMC Developmental Biology (2007) (In Press).
127. KATOH M, MATSUI T, OKUMURA H et al.: Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab. Dispos. (2005) 33(9):1333-1340.
128. BROOKE EW, DAVIES SG, MULVANEY AW et al.: An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg. Med. Chem. (2003) 11 (7):1227-1234.
129. SANDY J, MUSHTAQ A, KAWAMURA A et al.: The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis - an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. (2002) 318(4):1071-1083.
130. SANDY J, HOLTON S, FULLAM E, SIM E, NOBLE M: Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. (2005) 14(3):775-782.
131. WANG H, WAGNER CR, HANNA PE: Irreversible inactivation of arylamine N-acetyltransferases in the presence of N -hydroxy-4-acetylaminobiphenyl: a comparison of human and hamster enzymes. Chem. Res. Toxicol. (2005) 18(2):183-197.
132. GUO Z, WAGNER CR, HANNA PE: Mass spectrometric investigation of the mechanism of inactivation of hamster arylamine N-acetyltransferase 1 by N-hydroxy-2-acetylaminofluorene. Chem. Res. Toxicol. (2004) 17(3):275-286.
133. EINISTO P, WATANABE M, ISHIDATE M, JR., NOHMI T: Mutagenicity of 30 chemicals in Salmonella typhimurium strains possessing different nitroreductase or O-acetyltransferase activities. Mutat. Res. (1991) 259(1):95-102.
134. MUSHTAQ A, PAYTON M, SIM E: The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. (2002) 277(14):12175-12181.
135. QIAO QA, YANG C, QU R et al.: A density functional theory study on the role of His-107 in arylamine N-acetyltransferase 2 acetylation. Biophys. Chem. (2006) 122(3):215-220.
136. FULLAM E, SIM E, NOBLE M: Structure and activity of arylamine N-acetyltransferase from Mycobacterium marinum. Acid Fast Club Meeting. Porton Down, UK (2006).
137. KAWAMURA A, GRAHAM J, WAGNER CR, HANNA PE, SIM E: Expression, purification and characterization of Syrian hamster arylamine N-acetyltransferase 2. Biochem. Society Structural Biology Meeting . Loughborough, UK (2003).
138. DELGODA R, LIAN LY, SANDY J, SIM E: NMR investigation of the catalytic mechanism of arylamine N-acetyltransferase from Salmonella typhimurium. Biochim. Biophys. Acta (2003) 1620(1-3):8-14.
139. POMPEO F, MUSHTAQ A, SIM E: Expression and purification of the rifamycin amide synthase, RifF, an enzyme homologous to the prokaryotic arylamine N-acetyltransferases. Protein Expr. Purif. (2002) 24(1):138-151.
140. YU TW, SHEN Y, DOI-KATAYAMA Y et al.: Direct evidence that the rifamycin polyketide synthase assembles polyketide chains processively. Proc. Natl. Acad. Sci. USA (1999) 96(16):9051-9056.
141. RODRIGUES-LIMA F, DAIROU J, DIAZ CL et al.: Cloning, functional expression and characterization of Mesorhizobium loti arylamine N-acetyltransferases: rhizobial symbiosis supplies leguminous plants with the xenobiotic N-acetylation pathway. Mol. Microbiol. (2006) 60(2)505-512.
142. DAIROU J, FLATTERS D, CHAFFOTTE AF et al.: Insight into the structure of Mesorhizobium loti arylamine N-acetyltransferase 2 (MLNAT2): a biochemical and computational study. FEDS Lett. (2006) 580(7):1780-1788.
143. PAYTON M, AUTY R, DELGODA R, EVERETT M, SIM E: Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J. Bacteriol. (1999) 181(4):1343-1347.
144. PAYTON M, GIFFORD C, SCHARTAU P et al.: Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis. Microbiology (2001) 147(12):3295-3302.
145. SHOLTO-DOUGLAS-VERNON C, SANDY J, VICTOR TC, SIM E, HELDEN PD: Mutational and expression analysis of tbnat and its response to isoniazid. J. Med. Microbiol. (2005) 54(Pt 12):1189-1197.
146. UPTON AM, MUSHTAQ A, VICTOR TC et al.: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol. (2001) 42(2):309-317.
147. ANDERTON MC, BHAKTA S, BESRA GS et al.: Characterization of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG. Mol. Microbiol. (2006) 59(1):181-192.
148. RENGARAJAN J, BLOOM BR, RUBIN EJ: Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. Acad. Sci. USA (2005) 102(23):8327-8332.
149. VAN DER GEIZE R, HEUSER T, YAM K et al.: A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc. Natl. Acad. Sci. USA (2007) 104:1947-1952.
150. JOHNSON N: Arylamine N-acetyltransferases in man and mouse. In: D. Phil. Thesis. Oxford University, UK (2001).